TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of HIV-negative participants accepting PrEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prosthesis cup position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Transversus Abdominis activation-ratio (TrA-AR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Eczema Area and Severity Index score (EASI75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ETDRS severity level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of symptomatic COVID-19
Endpoint domain: Adverse events/effects
Primary endpoint: Number of eligible patients that elect to participate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of participants satisfied with telemedicine visit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of subjects who lose at least 150 mL of subcutaneous fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of galectin_3 binding protein in urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant and effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment Emergent Adverse Events (TEAE) grade >3
Endpoint domain: Adverse events/effects
Primary endpoint: Structural and functional lung abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: New-onset cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NOL monitor values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall specificity of the C2i-Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients Experiencing Dose-limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with a serious adverse event occurring within 30 days following FMT
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with a non-serious adverse event occurring within 30 days following FMT
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Fasting Plasma Ghrelin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Timed Standardized Nutrient Drink Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from Baseline in Gastroparesis Cardinal Symptom Index (GCSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from Baseline in Daily Eats: Measuring Daily Eating Factors (DAILY EATS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in Total Body Weight Loss (TBWL) from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With an Investigators Global Assessment (IGA) Score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving Eczema Area Severity Index-75 (EASI-75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in kidney function as assessed by serum creatine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in kidney function as assessed by estimated glomerular rate (eGFR) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: EEG power spectrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Major pathological response (mPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy of eye-tracking assays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of regulatory B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Scores of handwriting competence for legibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores of handwriting competence for speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of handwriting competence for reversal of letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Oswestry disability index (MODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: I-Handy level inclinometer mobile app
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in skull dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in type 1 IFN GS score in lesional skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Standardized Swallowing Assessment (SSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants who Experience One or More Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and reactogenicity of the UFRJvac COVID-19 vaccine booster
Endpoint domain: Adverse events/effects
Primary endpoint: changes of global longitudinal strain value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urine volatile organic compounds composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with demonstrated Clinical Benefit Rate (CBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AGV success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcome score (KOOS Score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency and severity of adverse events (AE) and serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe hypogammaglobulinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of severe hypogammaglobulinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of sonrotoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration time curve from time zero up to the last quantifiable concentration (AUClast) of sonrotoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal elimination half life (T1/2) of sonrotoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: expression pattern of CLIC1 protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with groin complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants diagnosed with TB disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cumulative number of participants discontinuing due to adverse drug reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Number of commercial antibodies identifying prostate cancer biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative Change Ratio of Diaphragm Thickness Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VTE knowledge difference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VTE prophylaxis prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: VTE prophylaxis adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase-2 dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of ventilator weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Gingivitis Bleeding score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (NNC0471-0119,0-30min,basal-corrected)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (NNC0471-0119,0-t,basal-corrected)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Solicited Local and Systemic Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With SAEs, AEs of Special Interest, Medically Attended AEs, and AEs Leading to Study or Treatment Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Live Donor Screenings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Live Donor Approvals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ongoing pregnancy rate after the first embryo transfer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of acute GVHD (grade II-IV)
Endpoint domain: Adverse events/effects
Primary endpoint: Functional walking distance (FWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent change in pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Levels of Total Estradiol Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Inflammation biomarker 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inflammation biomarker 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inflammation biomarker 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inflammation biomarker 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inflammation biomarker 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neuropsychological Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent reduction in mean absolute neutrophil cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: DNA Damage Level by Cyclobutane Pyrimidine Dimer (CPD) Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detectable DNA Strand Breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of DNA Strand Breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cellular Damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from persistent atrial arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: levels of sclerostin, RANKL, MMP-9 and PGE2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric rating scale at flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of platelet ≥50*10E9/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total amount of Adseverin in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of 1-Alpha Defensin in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of sRANKL in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contact lens-related discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contact lens-related dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of renal disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overall Response Rate (ORR) by investigator assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor standard uptake value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Predictive ability of lung ultrasound scores for bronchopulmonary dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Speed of recovery time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence and severity of treatment emergent AEs/SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to detect intracranial hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Evidence of amyloid infiltration as measured by ECV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Δ stroke volume index (ΔSVi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-dose PC20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory markers level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Glycolysis metabolism dependencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nuclear factor-kB (NF-κB) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of CBD intake
Endpoint domain: Adverse events/effects
Primary endpoint: Skeletal muscle size and cross-sectional area (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Skeletal muscle fibre CSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Diaphragmatic and vastus lateralis muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bayley-III motor subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bayley-III cognitive subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration-time Curve from Time Zero to 28 Days (AUC0-28d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration-time Curve Over the Dosing Interval at Steady State (AUCtau_SS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to relapse of colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: screening performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative likelihood ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Image States Scale (BISS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Grade 3 or higher antibody-related reactogenicity and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in plasma HIV RNA from day 0 to day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants with HIV RNA < 50 copies/mL at day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of excellent functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Thirty Second Chair Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first event of VTE recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Treatment-related adverse events (TRAEs) leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Positive predictive value for Barrett's Esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Barrett's Esophagus prevalence in test negative subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: COVID-19 test positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of household contacts testing positive for SARS-CoV-2
Endpoint domain: Adverse events/effects
Primary endpoint: Good graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Urate Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase 2 Doses (RP2D)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recruitment capability
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intervention acceptability and appropriateness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completion of adherence counseling session
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Short Fall Efficacy Scale International (short FES-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 15-item Geriatric Depression Scale (GDS-15)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Modified Barthel ADL Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in intracerebral Aβ deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in PGI (PRACTIC Goal-setting Interview)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in urine microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Occurrence, severity, and frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Post-intervention external cephalic version success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of deep vein thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Changes in cognitive performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum insertion depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extracorporeal CO2 removal rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dialysis weaning success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to positivity in BD MGIT liquid culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Neutrophil to lymphocyte ratio (NLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Platelet to lymphocyte ratio (PLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ectropion severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal Maturation Index (VMI) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Macrovascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood Flow Measurements (Large Blood Vessels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood Flow Measurements (Cerebral Blood Vessels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Regulatory T (Treg) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in T helper (TH) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in T helper Th17 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in serum microbial metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving ASAS40 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain measured with VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiomyocyte Division
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Femoral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: General Comfort Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in VAS score for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breath Holding Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes